The Conference Board, a business research group, on Tuesday released the June update for its consumer confidence index.Economyread more
The Congressional Budget Office estimated Tuesday that the national debt will rise to 141% of the economy over the next 30 years — 11 percentage points lower than the agency...Economyread more
Investors are piling into gold, sending the precious metal to a six-year high on Monday, and analysts think the commodity has established a base to go even higher.Marketsread more
More than 150,000 former students of for-profit colleges filed a lawsuit against the U.S. Department of Education and Education Secretary Betsy DeVos on Tuesday, claiming the...Personal Financeread more
The yield on the benchmark 10-year Treasury note fell below 2% on Tuesday as investors looked for safety following the release of much weaker-than-expected confidence data.Bondsread more
Amazon announces that Amazon Prime Day will last for two days, starting July 15.Technologyread more
Investors plow into the precious metal amid the prospects for lower interest rates, a softer global economy and increased geopolitical tensions.Marketsread more
Buyers pulled away from the builders in May, even as affordability improved, thanks to lower mortgage rates.Real Estateread more
Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share held, for a total value of $188.24 per Allergan share.Biotech and Pharmaceuticalsread more
CNBC's Carl Quintanilla reports from Hanoi, ahead of the Trump-Xi trade meeting, to look at Vietnam's manufacturing boom and whether it can be sustained.Economyread more
Joe Biden could face some uncomfortable questions about his record on women this week at the first Democratic presidential debates in Miami.2020 Electionsread more
A novel Canadian treatment to halt the progression of multiple sclerosis (MS) is being hailed as revolutionary, after doctors and researchers used the new stem cell transplant method to treat the disease.
The results of the trial, published in The Lancet medical journal, showed long-term improvement of disease control in 23 out of 24 MS patients tested.
The treatment combined chemotherapy and a stem cell transplant. It halted relapses and the development of new brain lesions in 23 of 24 patients for a prolonged period, without the need for ongoing medication, reported online science news service Eureka News, citing The Lancet.
Eight of the 23 patients had a sustained improvement in their disability 7.5 years after treatment, according to The Lancet. However, one patient in the clinical trial died from the use of aggressive chemotherapy.
MS is a neurological condition that is caused when the immune system attacks the body. It is among the most common chronic inflammatory diseases of the central nervous system, with around 2 million people affected worldwide and no known cure.
Mark Freedman, who led the trial, said the results should be viewed with caution.
"The sample size of 24 patients is very small and no control group was used for comparison with the treatment group. Larger clinical trials will be important to confirm these results," he said in The Lancet.
"Since this is an aggressive treatment, the potential benefits should be weighed against the risks of serious complications," he added.
To read the full report in The Lancet, please click here.
Follow CNBC International on and Facebook.